Last reviewed · How we verify
NCT06715891
Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 Years
Phase 3 trial testing Raphamin in Acute Respiratory Viral Infection in 374 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Materia Medica Holding |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 374 |
| Start date | 11 November 2024 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 35 locations across Russia |
Drugs / interventions tested
- Raphamin — full drug profile →
- Placebo
Conditions studied
- Acute Respiratory Viral Infection — all drugs for Acute Respiratory Viral Infection →
Sponsor
Materia Medica Holding — full company profile →
Who can join
Adults 3 to 12, any sex, with Acute Respiratory Viral Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Multicenter double-blind placebo-controlled randomized in parallel groups clinical trial.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06715891
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Raphamin
Trials testing the same drug.
- NCT06901297 — The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients · Phase 3 · recruiting
- NCT06263881 — Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia · Phase 3 · completed
- NCT06284265 — Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial Cystitis · Phase 3 · active not recruiting
- NCT05364671 — Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients · Phase 3 · completed
- NCT04918771 — Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old · Phase 3 · completed
Other recruiting trials for Acute Respiratory Viral Infection
Currently open trials in the same condition.
- NCT07420985 — Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Differen · Phase 2 · recruiting
Other Materia Medica Holding trials
Trials by the same sponsor.
- NCT07171099 — Efficacy and Safety of Rengalin in the Treatment of ARVI Cough in Children · Phase 3 · recruiting
- NCT06901297 — The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients · Phase 3 · recruiting
- NCT06263881 — Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia · Phase 3 · completed
- NCT06284265 — Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial Cystitis · Phase 3 · active not recruiting
- NCT05364671 — Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06715891 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Materia Medica Holding
- Last refreshed: 13 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06715891.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing